Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Iqvia Holdings Inc (IQV)

Iqvia Holdings Inc (IQV)
165.00 x 1 183.50 x 6
Pre-market by (Cboe BZX)
174.37 +3.13 (+1.83%) 04/02/25 [NYSE]
165.00 x 1 183.50 x 6
Pre-market 170.80 -3.57 (-2.05%) 08:13 ET
Quote Overview for Thu, Apr 3rd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
170.80
Day High
170.80
Open 170.80
Previous Close 174.37 174.37
Volume 1,128 1,128
Avg Vol 1,503,166 1,503,166
Stochastic %K 14.17% 14.17%
Weighted Alpha -32.45 -32.45
5-Day Change -8.56 (-4.77%) -8.56 (-4.77%)
52-Week Range 169.11 - 252.88 169.11 - 252.88
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,744,044
  • Shares Outstanding, K 176,315
  • Annual Sales, $ 15,405 M
  • Annual Income, $ 1,373 M
  • EBIT $ 3,316 M
  • EBITDA $ 4,451 M
  • 60-Month Beta 1.46
  • Price/Sales 1.96
  • Price/Cash Flow 10.31
  • Price/Book 5.12

Options Overview Details

View History
  • Implied Volatility 36.14% ( +0.99%)
  • Historical Volatility 26.11%
  • IV Percentile 93%
  • IV Rank 79.81%
  • IV High 40.05% on 10/22/24
  • IV Low 20.68% on 05/09/24
  • Put/Call Vol Ratio 0.43
  • Today's Volume 172
  • Volume Avg (30-Day) 295
  • Put/Call OI Ratio 1.49
  • Today's Open Interest 6,507
  • Open Int (30-Day) 10,253

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.37
  • Number of Estimates 7
  • High Estimate 2.40
  • Low Estimate 2.27
  • Prior Year 2.30
  • Growth Rate Est. (year over year) +3.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
169.11 +1.00%
on 04/02/25
Period Open: 184.85
193.01 -11.51%
on 03/10/25
-14.05 (-7.60%)
since 03/03/25
3-Month
169.11 +1.00%
on 04/02/25
Period Open: 197.39
220.00 -22.36%
on 02/06/25
-26.59 (-13.47%)
since 01/03/25
52-Week
169.11 +1.00%
on 04/02/25
Period Open: 242.98
252.88 -32.46%
on 08/29/24
-72.18 (-29.71%)
since 04/03/24

Most Recent Stories

More News
Paychex Q3 Earnings & Revenues Surpass Estimates, Increase Y/Y

Paychex, Inc. PAYX has reported impressive third-quarter fiscal 2025 results, wherein earnings and revenues beat the Zacks Consensus Estimate.See Zacks Earnings Calendar to stay ahead of market-making...

PAYX : 153.46 (-0.96%)
IT : 411.12 (-3.12%)
IQV : 170.80 (-2.05%)
Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

Winners And Losers Of Q4: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

FTRE : 7.32 (-2.53%)
UFPT : 210.79 (+3.36%)
AZTA : 35.41 (+3.78%)
RGEN : 130.92 (+1.88%)
IQV : 170.80 (-2.05%)
Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks

Unpacking Q4 Earnings: West Pharmaceutical Services (NYSE:WST) In The Context Of Other Drug Development Inputs & Services Stocks

FTRE : 7.32 (-2.53%)
UFPT : 210.79 (+3.36%)
AZTA : 35.41 (+3.78%)
WST : 215.88 (-2.54%)
IQV : 170.80 (-2.05%)
3 Reasons IQV is Risky and 1 Stock to Buy Instead

3 Reasons IQV is Risky and 1 Stock to Buy Instead

CRWD : 351.00 (-5.52%)
IQV : 170.80 (-2.05%)
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)

Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)

FTRE : 7.32 (-2.53%)
MEDP : 311.23 (+4.53%)
AZTA : 35.41 (+3.78%)
WST : 215.88 (-2.54%)
IQV : 170.80 (-2.05%)
Is IQVIA Holdings Stock Underperforming the Dow?

IQVIA Holdings has significantly underperformed the Dow over the past year, yet analysts remain strongly bullish on the stock’s prospects.

A : 115.99 (+1.70%)
$DOWI : 42,225.32 (+0.56%)
IQV : 170.80 (-2.05%)
IQV : 170.80 (-2.05%)
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack

FTRE : 7.32 (-2.53%)
MEDP : 311.23 (+4.53%)
RGEN : 130.92 (+1.88%)
AZTA : 35.41 (+3.78%)
IQV : 170.80 (-2.05%)
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4

Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4

FTRE : 7.32 (-2.53%)
MEDP : 311.23 (+4.53%)
AZTA : 35.41 (+3.78%)
CRL : 149.28 (+2.25%)
IQV : 170.80 (-2.05%)
Rep. Marjorie Taylor Greene Is Betting Big on Nvidia Stock. Should You?

The politician last disclosed a purchase worth up to $15,000 in NVDA in January.

NVDA : 103.81 (-5.99%)
GOOGL : 150.33 (-4.27%)
AAPL : 207.41 (-7.36%)
TSLA : 265.39 (-6.14%)
ILMN : 78.75 (-3.82%)
MET : 78.99 (-4.24%)
AMZN : 181.75 (-7.28%)
IQV : 170.80 (-2.05%)
IQVIA Holdings Stock: Analyst Estimates & Ratings

IQVIA Holdings has trailed the broader market over the past year, but analysts on Wall Street maintain a very bright outlook on the stock’s growth prospects.

XLV : 143.45 (-0.59%)
$SPX : 5,670.97 (+0.67%)
JPM : 234.99 (-4.41%)
IQV : 170.80 (-2.05%)
NVIDIA's Rise Puts These 3 Healthcare Stocks in the Spotlight

Graphic processing units (GPUs) and artificial intelligence (AI) are among the most searched terms online these days, making companies like NVIDIA NVDA the focal point of investors’ interest. While NVIDIA’s...

NVDA : 103.81 (-5.99%)
ILMN : 78.75 (-3.82%)
DXCM : 65.12 (-4.43%)
IQV : 170.80 (-2.05%)
Waste Connections Q4 Earnings Miss Estimates, Revenues Rise Y/Y

Waste Connections. Inc. WCN reported mixed fourth-quarter 2024 results, wherein earnings missed the Zacks Consensus Estimates, while revenues beat the same.See Zacks Earnings Calendar to stay ahead of...

WCN : 196.62 (+0.06%)
RSG : 240.25 (-1.87%)
IQV : 170.80 (-2.05%)
Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow

Earnings To Watch: Charles River Laboratories (CRL) Reports Q4 Results Tomorrow

AZTA : 35.41 (+3.78%)
CRL : 149.28 (+2.25%)
IQV : 170.80 (-2.05%)
Nvidia Could Power Up This Under-the-Radar Healthcare Stock

A partnership with Nvidia is bound to yield fruitful results for this little-known company.

SERV : 5.21 (-11.41%)
NVDA : 103.81 (-5.99%)
SOUN : 7.91 (-8.66%)
$SPX : 5,670.97 (+0.67%)
IQV : 170.80 (-2.05%)
West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For

West Pharmaceutical Services (WST) Q4 Earnings Report Preview: What To Look For

AZTA : 35.41 (+3.78%)
WST : 215.88 (-2.54%)
IQV : 170.80 (-2.05%)
S&P Global Q4 Earnings & Revenues Surpass Estimates, Increase Y/Y

S&P Global Inc. SPGI has reported impressive fourth-quarter 2024 results, wherein earnings and revenues outpaced the Zacks Consensus Estimate.See Zacks Earnings Calendar to stay ahead of market-making...

EFX : 243.90 (-1.48%)
SPGI : 497.01 (-3.30%)
IQV : 170.80 (-2.05%)
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect

Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect

MEDP : 311.23 (+4.53%)
AZTA : 35.41 (+3.78%)
IQV : 170.80 (-2.05%)
IQVIA Earnings & Revenues Surpass Estimates in Q4, Increase Y/Y

IQVIA Holdings Analytics Inc. IQV has reported impressive fourth-quarter 2024 results, wherein earnings and revenues beat the Zacks Consensus Estimate.See Zacks Earnings Calendar to stay ahead of market-making...

BR : 238.86 (-3.00%)
IT : 411.12 (-3.12%)
IQV : 170.80 (-2.05%)
IQVIA (NYSE:IQV) Exceeds Q4 Expectations, Stock Soars

IQVIA (NYSE:IQV) Exceeds Q4 Expectations, Stock Soars

IQV : 170.80 (-2.05%)
IQVIA: Q4 Earnings Snapshot

IQVIA: Q4 Earnings Snapshot

IQV : 170.80 (-2.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

IQVIA Holdings Inc. provides advanced analytics, technology solutions and contract research services to the life sciences industry. The company was formed through the merger of IMS Health (RX) and Quintiles. The company is focused on helping healthcare clients to better serve patients by bringing in...

See More

Key Turning Points

3rd Resistance Point 181.78
2nd Resistance Point 178.20
1st Resistance Point 176.28
Last Price 170.80
1st Support Level 170.78
2nd Support Level 167.20
3rd Support Level 165.28

See More

52-Week High 252.88
Fibonacci 61.8% 220.88
Fibonacci 50% 210.99
Fibonacci 38.2% 201.11
Last Price 170.80
52-Week Low 169.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Trader's Cheat Sheet: Your Secret Weapon for Smarter Trades